Revenue Exceeds Guidance
Total revenue of $1.08 billion, above guidance range. Non-GAAP operating margin was 24.5% and non-GAAP diluted EPS was $1.34, both above guidance.
Strong Performance in Clinical Markets
Sequencing consumables revenue grew at a high single-digit rate year-over-year. Clinical remains a primary driver, supported by new assay approvals and increased demand for sequencing-intensive tests.
Successful NovaSeq X Transition
More than 55 instruments placed in Q3, exceeding the goal of 50-60 placements per quarter. 78% of volumes and 51% of revenue in Q3 were sequenced on the NovaSeq X.
Expansion in Multiomics
Launch of Illumina Protein Prep and expansion of the multiomics portfolio with the 5-base solution. Progressing with the acquisition of SomaLogic, expected to close in 2026.
Increased Full-Year Outlook
Raising full-year 2025 outlook due to strong Q3 performance and resilience in clinical markets.